Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Harvard Bioscience ( (HBIO) ) has provided an announcement.
On January 23, 2026, Harvard Bioscience’s board approved “Project Viking,” a strategic consolidation of manufacturing aimed at improving efficiency and supporting long-term growth, centered on closing the Holliston, Massachusetts facility and shifting U.S. production to the company’s Minneapolis, Minnesota hub, while relocating certain operations to centers of excellence in Germany, Sweden and the UK. The Holliston plant will remain operational through 2026, with the phased consolidation expected to be substantially complete by the first quarter of 2027, generating an estimated $3 million in cost savings in 2027 and about $4 million in annual savings thereafter, driven by reduced overhead, SKU rationalization, better asset utilization and workforce reconfiguration, although the company expects to incur $3.4 million to $4.4 million in pre-tax restructuring charges and transition-related operating expenses through the first half of 2027 as it seeks to streamline its footprint, improve execution and enhance long-term value for customers and shareholders.
The most recent analyst rating on (HBIO) stock is a Hold with a $0.65 price target. To see the full list of analyst forecasts on Harvard Bioscience stock, see the HBIO Stock Forecast page.
Spark’s Take on HBIO Stock
According to Spark, TipRanks’ AI Analyst, HBIO is a Neutral.
The score is held back primarily by weak financial performance (declining revenue, losses, and leverage), with only partial support from improving cash flow. The earnings call was a relative positive—showing margin/EBITDA improvement, cost discipline, better cash generation, and debt reduction—but technical indicators remain soft and valuation is not informative due to negative earnings.
To see Spark’s full report on HBIO stock, click here.
More about Harvard Bioscience
Harvard Bioscience, Inc. is a leading developer, manufacturer and seller of technologies, products and services that support life science applications, including research, drug and therapy discovery, bio-production and preclinical testing for pharmaceutical and therapy development. Serving academic institutions, government laboratories, and major pharmaceutical, biotechnology and contract research organizations, the company operates in the United States, Europe and China and sells globally through both direct and distribution channels.
Average Trading Volume: 6,377,307
Technical Sentiment Signal: Strong Sell
Current Market Cap: $26.44M
See more insights into HBIO stock on TipRanks’ Stock Analysis page.